
Gene delivery evolution: Advancing novel cancer immunotherapies
DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company's cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More

